1. Home
  2. WMK vs GLTO Comparison

WMK vs GLTO Comparison

Compare WMK & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weis Markets Inc.

WMK

Weis Markets Inc.

N/A

Current Price

$62.25

Market Cap

1.8B

ML Signal

N/A

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$28.17

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WMK
GLTO
Founded
1912
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
WMK
GLTO
Price
$62.25
$28.17
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$43.67
AVG Volume (30 Days)
127.7K
362.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.21%
N/A
EPS Growth
5.96
N/A
EPS
2.51
N/A
Revenue
$4,714,573,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.70
N/A
Revenue Growth
0.01
N/A
52 Week Low
$61.27
$2.01
52 Week High
$90.23
$38.33

Technical Indicators

Market Signals
Indicator
WMK
GLTO
Relative Strength Index (RSI) 30.22 51.77
Support Level N/A $24.53
Resistance Level $68.14 $32.86
Average True Range (ATR) 2.29 2.50
MACD -1.04 -0.30
Stochastic Oscillator 6.14 29.94

Price Performance

Historical Comparison
WMK
GLTO

About WMK Weis Markets Inc.

Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: